Biomapas Enters US Market with Acquisition of Alira Health's CMC Business

Biomapas has acquired the Chemistry, Manufacturing and Controls (CMC) business of Alira Health, marking the life sciences services provider's entry into the US market. The Boston-based team will form the foundation of Biomapas North America, the company's new US business.

The CMC team, made up of more than 35 specialists, supports preclinical- and clinical-stage biopharma companies with outsourced clinical manufacturing, quality assurance oversight, CMC regulatory strategy and filings, and project management. Its experience covers complex biologics, including monoclonal antibodies, ADCs, oligonucleotides, CAR-T and other cell therapies, as well as small molecules and peptides. The team has worked with more than 90 clients in the US and Europe.

The acquisition adds a CMC service line to Biomapas' existing regulatory affairs, pharmacovigilance, clinical development and digital and consulting services. Current clients will continue working with the same team and contacts, and Biomapas plans to use the North American business to offer its wider services to US sponsors over time.

Biomapas CEO Xavier Duburcq said the US is the largest market for the company's clients. He added that CMC sits upstream of Biomapas' existing services, allowing the company to support clients earlier in development.

Sean Forestell, now Senior Vice President, CMC Operations at Biomapas, said the move gives the team a broader platform to reach more sponsors and gives clients access to regulatory, safety, clinical and digital support from a single partner.

Biomapas is majority-owned by Carbyne Equity Partners, which has backed the company since October 2024. The deal follows Biomapas' acquisitions of Delta PV in 2025 and Pinnaxis in 2026.


Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers from Pharmaceutical Outsourcing - all delivered right to your inbox! Sign up now!

  • <<
  • >>

Join the Discussion